Crossmark

Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism

Crossref DOI link: https://doi.org/10.1007/s11239-018-1695-1

Published Online: 2018-06-07

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Coleman, Craig I. https://orcid.org/0000-0003-4868-7158
Turpie, Alexander G. G.

Bunz, Thomas J.

Beyer-Westendorf, Jan
Funding

Funding for this research was provided by:

Bayer AG
License Information

Text and Data Mining valid from 2018-06-07
More Information

Article History

First Online: 7 June 2018

Compliance with ethical standards

:

: Dr. Coleman has received research grants from Bayer AG and Janssen Pharmaceuticals. He has served as a consultant for Boehringer Ingelheim, Janssen Pharmaceuticals, Bayer AG, Portola Pharmaceuticals and Medscape. Dr. Turpie has received speaker’s honoraria and consultancy fees from, and participated in scientific advisory boards for, Bayer HealthCare Pharmaceuticals and Janssen Research & Development, LLC, and has been a consultant for Bayer HealthCare, Janssen Pharmaceutical Research & Development, Astellas, Portola and Takeda. Dr. Beyer-Westendorf has received research grants from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Portola Pharmaceuticals, and has served as a consultant to and has received honoraria from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Portola Pharmaceuticals, CSL Behring and Medscape. Dr. Bunz have no relevant disclosures.

: This study was determined to not constitute research involving human subjects according to 45 CFR 46.102(f), and therefore, deemed exempt from institutional review board oversight.